Pharmaceutical Industry Faces 2030 Patent Cliff as a Catalyst for Strategic Innovation

As the pharmaceutical industry braces for a significant patent cliff looming in 2030, companies are urged to treat this development as a potential avenue for strategic renewal. The expiration of patents for blockbuster drugs such as Eliquis, Keytruda, and Stelara could reshape the landscape of global drug sales, presenting a pivotal moment for industry leaders. Firms that adapt and innovate in response to these challenges are likely to secure and maintain market leadership. Insights into this topic, including strategic approaches to this industry shift, are provided by Keegan Caldwell at Caldwell Law. For an in-depth analysis, the original discussion can be accessed here.